Zitong Palace (920566) used 90 million yuan of its own funds to purchase financial products, improving the efficiency of its own capital utilization.

On March 18, Sichuan Zitong Palace Pharmaceutical Co., Ltd. announced that the company has purchased financial products with its idle funds amounting to 90 million RMB. As of now, the company’s remaining balance of idle funds used for purchasing financial products that have not yet matured is 250 million RMB.

Zitong Palace stated in the announcement that, to improve the efficiency of fund utilization and increase investment returns, and without affecting the normal development of the company’s main business and ensuring normal operational needs, the company plans to use no more than 250 million RMB of its idle funds to purchase low-risk short-term financial products.

According to industry sources, the company is a national high-tech enterprise engaged in drug research, development, production, and marketing. The company currently holds 26 invention patents and 99 drug approval numbers, with various dosage forms including tablets, hard capsules, powders, ointments, and creams. The company has established a research and development pattern focused on neurological, digestive, and pain-relief drugs as leading areas, with future development priorities including drugs for the nervous system, digestive system, endocrine system, pain relief, and gynecology.

The company’s newly launched products include Sodium Choline Phospholipid Tablets, Rizatriptan Benzoate Capsules, Celecoxib Capsules, Oseltamivir Phosphate Capsules, Pregabalin Oral Solution, and Dongfang Gua Medicine Capsules. Additionally, its controlling subsidiary, Kunming Zitong Palace, owns exclusive national traditional medicine products such as Qingchang Tongbian Capsules, Xuanju Capsules, Huzhang Wound Ointment, as well as over 40 core and common medicines with competitive advantages in Yunnan Province.

The company is recognized as a national high-tech enterprise, a national intellectual property advantage enterprise, and a “Specialized, Refined, Characteristic, and Innovative” small and medium-sized enterprise in Sichuan Province. Its R&D team has solid theoretical foundations, rich practical experience, and outstanding innovation capabilities. Several company leaders have over 30 years of research and leadership experience in the pharmaceutical industry, with R&D directors and key technical personnel each possessing more than 20 years of frontline experience in pharmaceutical research and manufacturing. The company actively collaborates with domestic and international universities, leveraging external resources, introducing advanced international technologies, and enhancing its R&D capabilities. Kunming Zitong Palace Technology Center was recognized as the “2022 Kunming City Enterprise Technology Center,” further strengthening innovation and R&D, and solidifying the technological R&D platform.

After twenty years of operation, the company has established a strong brand reputation in the pharmaceutical industry through excellent product quality and business integrity. Through independent innovation, the company’s technology center has become a provincial-level enterprise technology center. Initiatives such as brand promotion, patent applications, and the application for a Chinese time-honored brand have continuously increased the company’s intangible assets, market influence, and brand value. Additionally, leveraging the sales team and the influence of research institutes and experts, the company’s brand awareness has been further enhanced, creating a positive cycle that supports rapid development.

The company actively responds to market changes by continuously optimizing product structure and market layout. It enhances online marketing by participating in live broadcasts through third-party e-commerce platforms, increasing brand visibility and product sales. The company actively participates in various pharmaceutical exhibitions, expos, academic conferences, and innovation forums to showcase its product advantages and enhance brand influence. It also participates in centralized procurement, advancing tendering and listing across provinces, and expanding the depth and breadth of the domestic market. Its product Pregabalin Oral Solution was selected in the 10th batch of national drug centralized procurement. The new product Celecoxib Capsules has rapidly increased in volume, while sales of existing products such as Dongfang Gua Medicine Capsules and Rizatriptan Benzoate Capsules have significantly grown.

In the first half of 2025, the company’s new drug R&D projects are progressing steadily. The application for registration and approval of Fumaric Venoate Tablets has been accepted; Phase I clinical trials of the innovative drug Majiashi Capsules are underway; generic drugs such as Glucosamine Sulfate Capsules and Ibuprofen Extended-Release Capsules have entered pilot production. Meanwhile, through collaborations with research enterprises and major universities, the company is seeking multi-channel and diversified mechanisms for transforming R&D achievements into practical products, aiming to realize rapid conversion of research results.

In terms of performance, in the first three quarters of 2025, the company achieved operating revenue of 303 million RMB and a net profit attributable to shareholders of 56.1 million RMB.